Indinavir is a protease inhibitor that has been found to be extremely effective for patients with HIV and acquired immunodeficiency syndrome ( AIDS). 茚地那韦属于蛋白酶抑制剂,是一种抗病毒药物,已用于治疗HIV感染及获得性免疫缺陷综合征(AIDS)病人。
We review the incidence, mechanism of formation, diagnosis and treatment of indinavir urolithiasis, and suggest how to prevent stone formation. 本文综述了茚地那韦尿路结石的发病率、形成机制、诊断与治疗方法,并对如何预防茚地那韦尿路结石提出了建议。
However, of all protease inhibitors currently in use, indinavir is associated with the greatest risk for the development of urolithiasis. 同其他蛋白酶抑制剂相比,茚地那韦形成尿路结石的危险最大。
LC/ MS/ MS determination of indinavir in human plasma LC/MS/MS测定人血浆中茚地那韦的浓度
Study on the Efficacy and Safety of Highly Active Antiretroviral Therapy Combining Indinavir with Efavirenz in Chinese HIV/ AIDS Patients 佳息患联合施多宁治疗中国HIV/AIDS患者的疗效和安全性研究
RESULTS: Cocktail therapy including the indinavir have a best results, can rise their CD4 cell counts and lower plasma HIV viral load. 结果:采用包括依地那韦在内的三联疗法在提高CD4细胞计数,降低HIV病毒负荷疗效最好。
Study on pharmacodynamics and pharmacokinetics of HIV protease inhibitor Indinavir and its treatment for AIDS HIV蛋白酶抑制剂依地那韦药效学、药动学及治疗艾滋病的临床应用
OBJECTIVE: To recommend the protease inhibitors Indinavir for AIDS treatment. 目的:介绍蛋白酶抑制剂依地那韦治疗艾滋病。
Conclusions The characteristics of metabolic stability of indinavir in SD rat, monkey and beagle dog liver microsomes were similar to human. 结论:茚地那韦在SD大鼠、猕猴和比格犬肝微粒体的代谢特征与其在人肝微粒体上的代谢特征相似。